Profound Medical, a Toronto-based medical technology company focused on minimally invasive treatments for prostate cancer and other conditions, said its fiscal third-quarter revenue likely climbed 85% to 89% from a year earlier, to between $9.8 million and $10.0 million. The preannouncement, issued ahead of the company's full earnings report on Nov. 5, sent shares up about 14% in after-hours trading.
The update suggests a significant acceleration in sales. In the same quarter last year, the company reported revenue of $5.3 million, so the projected range represents a near-doubling of the top line. For a company of Profound's size, that kind of growth is notable and points to stronger adoption of its products.
What's driving the growth?
CEO Arun Menawat attributed the jump to two main factors: higher activity at existing customer sites—what the company calls its installed base—and new account wins. That distinction matters because recurring usage from existing customers can be more predictable and durable than one-off equipment sales. If hospitals and clinics are using Profound's systems more frequently, that suggests the technology is becoming embedded in their workflows, which could support future revenue.
Profound Medical's flagship product is the TULSA-PRO, a device that uses MRI-guided focused ultrasound to treat prostate tissue. The company also sells the Sonalleve system for uterine fibroids and other indications. These are capital equipment sales, but they come with consumables and service contracts, so the revenue model has a recurring component.
The preannouncement is a common move for companies when they want to manage expectations ahead of a formal earnings release. By putting the revenue range out early, Profound has removed some of the uncertainty about the headline number. That can be a double-edged sword: it reduces the risk of a negative surprise, but it also raises the bar for the actual report.
What investors will watch on Nov. 5
With the revenue figure largely known, the focus shifts to the quality of the growth. Analysts and investors will want to know how much of the increase came from existing customers using the systems more intensively versus new customers coming on board. They'll also look for signs that the momentum can continue into the next quarter and beyond.
Another key question is profitability. While revenue growth is impressive, investors will be watching whether the company is making progress on margins or if it's spending heavily to fuel that growth. Profound Medical has been investing in sales and marketing, and the earnings report will show whether those costs are being managed.
The after-hours pop to around $6.50 suggests traders quickly repriced the near-term outlook once the uncertainty fell. But as with any preannouncement, the stock's next move often depends less on confirming the quarter and more on the forward-looking commentary. If management can show that demand is durable and that the next quarter's setup supports higher revenue expectations, the stock could hold its gains. If not, the initial pop could fade.
What it means for everyday investors
For investors, preannouncements like this are a reminder that the market doesn't just react to numbers—it reacts to surprises. When a company gives you the headline number early, the surprise is gone, and the focus turns to the details. That's why you'll often see stocks move more on guidance than on the actual results.
Profound Medical is a small-cap medtech company, which means its shares can be volatile. A 14% after-hours move is significant, but it's not unusual for a company of this size. Investors should be prepared for swings around earnings.
The broader context is also worth noting. Medtech companies have been benefiting from a recovery in elective procedures and hospital spending after the pandemic slowdown. Profound's growth is consistent with that trend, but it's also company-specific—the TULSA-PRO has been gaining traction as a less invasive alternative to surgery for prostate cancer.
For those considering an investment, the key is to look beyond the headline revenue number. Check the earnings call for details on the installed base, new customer wins, and any commentary on the pipeline. Also, consider the company's cash position and burn rate, as small-cap medtech firms often need to raise capital to fund growth.
As always, this is not a recommendation to buy or sell. It's an explanation of what the news means and what to watch for. The full earnings report on Nov. 5 will provide more clarity on whether this growth is sustainable.
